|Mr. Shinichi Tamura||Founder & Chairman||1.1M||N/A||1949|
|Mr. Chris Cargill||Representative Exec. Officer, Pres, CEO & Director||760.45k||N/A||1984|
|Mr. Hironoshin Nomura||Sr. VP of Investor Relations, VP & Corp. Strategy, Exec. Officer and CFO||N/A||N/A||N/A|
|Mr. Kieran Johnson F.C.A.||Exec. Officer, VP & Chief Accounting Officer||N/A||N/A||N/A|
|Dr. Miles Congreve||Chief Scientific Officer||N/A||N/A||N/A|
|Mr. Kazuhiko Yoshizumi||Exec. Officer, VP & Chief Compliance Officer||N/A||N/A||1954|
|Candelle Chong||VP of Corp. Strategy & Communications||N/A||N/A||N/A|
|Shinichiro Nishishita||VP of Investor Relations & Head of Regulatory Disclosures||N/A||N/A||N/A|
|Dr. Barry Kenny Ph.D.||Chief Bus. Officer of Bus. Devel.||N/A||N/A||N/A|
|Stacey Southall||Associate Director & Head of Biophysics||N/A||N/A||N/A|
Sosei Group Corporation develops biopharmaceutical products worldwide. Its marketed products include Ultibro/Breezhaler and Seebri/Breezhaler for the treatment of chronic obstructive pulmonary disease; Enerzair to treat asthma; and ORAVI, an oropharyngeal candidiasis. The company's product pipeline consists of HTL0022562, a calcitonin gene related peptide antagonist, which is in Phase I clinical study; HTL0016878 for neurological diseases; PF-07081532 for Type 2 diabetes mellitus and obesity; PF-07054894 for inflammatory bowel disease; PF-07258669 for anorexia; and TMP301 and BHV3100 for neurological disorders, which is in clinical trials. Sosei Group Corporation has a strategic collaboration with AbbVie, Biohaven, Genentech, GSK, Takeda, Pfizer, AstraZeneca, and Takeda. The company was incorporated in 1990 and is headquartered in Tokyo, Japan.
Sosei Group Corporation’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.